Cargando…

Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease

Endothelial dysfunction underlies multiple cardiovascular consequences of chronic kidney disease (CKD) and antecedent diabetes or hypertension. Endothelial insults in CKD or end-stage renal disease (ESRD) patients include uremic toxins, serum uric acid, hyperphosphatemia, reactive oxygen species, an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rastogi, Anjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917706/ https://www.ncbi.nlm.nih.gov/pubmed/24327730 http://dx.doi.org/10.1177/1753944713513061

Ejemplares similares

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)

Sevelamer carbonate experience in Indian end stage renal disease patients
por: Abraham, G., et al.
Publicado: (2012)

Sevelamer-Associated Rectosigmoid Ulcers in an End-Stage Renal Disease Patient
por: Uy, Pearl Princess, et al.
Publicado: (2018)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients
por: Ossareh, Shahrzad
Publicado: (2014)

Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
por: Lenglet, Aurelie, et al.
Publicado: (2021)

Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients
por: Rosa-Diez, Guillermo, et al.
Publicado: (2016)

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis
por: Fan, Stanley, et al.
Publicado: (2009)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Sevelamer reduces endothelial inflammatory response to advanced glycation end products
por: Gregório, Paulo C, et al.
Publicado: (2018)

Colonic Mucosal Ulceration and Gastrointestinal Bleeding Associated with Sevelamer Crystal Deposition in a Patient with End Stage Renal Disease
por: Nambiar, Sudheer, et al.
Publicado: (2018)

Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease
por: Mason, Darius L., et al.
Publicado: (2021)

A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis
por: Zhou, Tianbiao, et al.
Publicado: (2018)

Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China
por: Meng, Lin, et al.
Publicado: (2015)

Update and critical appraisal of sevelamer in the management of chronic renal failure
por: Grinfeld, Jacob, et al.
Publicado: (2010)

Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death
por: Dalrymple, Lorien S., et al.
Publicado: (2010)

End Stage and Chronic Kidney Disease: Associations with Renal Cancer
por: Russo, Paul
Publicado: (2012)

Association of Constipation with risk of end-stage renal disease in patients with chronic kidney disease
por: Lu, Chung-Yen, et al.
Publicado: (2019)

Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death
por: Borg, Rikke, et al.
Publicado: (2023)

Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease
por: Vlad, Cristiana-Elena, et al.
Publicado: (2019)

Preoperative Evaluation in Patients With End-Stage Renal Disease and Chronic Kidney Disease
por: Nasr, Rabih, et al.
Publicado: (2017)

Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease
por: Mathew, Roy O, et al.
Publicado: (2016)

Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease
por: Makowka, Agnieszka, et al.
Publicado: (2021)

Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
por: Nain, Parminder, et al.
Publicado: (2023)

Revisiting the association between human leukocyte antigen and end-stage renal disease
por: Noureen, Naila, et al.
Publicado: (2020)

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3
por: Bouma-de Krijger, Annet, et al.
Publicado: (2019)

Cardiovascular risk in children and adolescents with end stage renal disease
por: do Val, Maria Luiza, et al.
Publicado: (2019)

Comparison of the Quality of Sleep in Patients With Chronic Kidney Disease and End-Stage Renal Disease
por: Mujahid, Mehreen, et al.
Publicado: (2022)

Cardiovascular Disease in Patients with End-Stage Renal Disease on Hemodialysis
por: Aoki, Jiro, et al.
Publicado: (2017)

Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial
por: Chue, Colin D, et al.
Publicado: (2011)

Relative risks of Chronic Kidney Disease for mortality and End Stage Renal Disease across races is similar
por: Wen, Chi-Pang, et al.
Publicado: (2014)

Artificial Intelligence for Risk Prediction of End-Stage Renal Disease in Sepsis Survivors with Chronic Kidney Disease
por: Lee, Kuo-Hua, et al.
Publicado: (2022)

Pleiotropic effects of vitamin D in an early stage of chronic kidney disease—effect on insulin resistance
por: Xydakis, Dimitris, et al.
Publicado: (2010)

Uremic and Post-Transplant Gastropathy in Patients With Chronic Kidney Disease and End-Stage Renal Disease
por: Turshudzhyan, Alla, et al.
Publicado: (2020)

Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug–Bug Interaction?
por: Dai, Lu, et al.
Publicado: (2020)

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
por: Nguyen, Hai V., et al.
Publicado: (2016)

Pleiotropic functions of TIMP-1 in patients with chronic kidney disease
por: Musiał, Kinga, et al.
Publicado: (2014)

Diagnosis and Management of Cardiovascular Disease in Advanced and End‐Stage Renal Disease
por: Bhatti, Navdeep K., et al.
Publicado: (2016)

Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease
por: Wang, Yinghui, et al.
Publicado: (2022)

Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies
por: Cherng, Yih-Giun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8na844gca8ucu3664abl8f0pvi